Substance / Medication

Cefaclor

Overview

Active Ingredient
cefaclor
RxNorm CUI
2176

Indications

Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media Streptococcus pneumoniae, Haemophilus influenzae Streptococcus pyogenes caused by, staphylococci, and Note: Haemophilus influenzae in vitro β-lactamase-negative, ampicillin-resistant (BLNAR) strains ofshould be considered resistant to cefaclor despite apparentsusceptibility of some BLNAR strains. Lower respiratory tract infections Streptococcus pneu

Labeler: Rebel Distributors CorpUpdated: 2011-07-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Cefaclor is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Exploring the pharmacokinetics of second-generation cephalosporin, cefaclor: a systematic review in healthy and diseased populations.
Saleem Tahir, Zamir Ammara, Rasool Muhammad Fawad et al. · Xenobiotica · 2024
PMID: 38517680Meta-Analysis
Effects of cefaclor on gastric emptying and cholecystokinin release in healthy humans.
Ma Jing, Bellon Max, Wishart Judith M et al. · Regul Pept · 2010
PMID: 19914303RCT
Comparative efficacy and safety evaluation of cefaclor vs amoxycillin + clavulanate in children with Acute Otitis Media (AOM).
Aggarwal Mukesh, Sinha Ramanuj, Murali M Vasudeva et al. · Indian J Pediatr · 2005
PMID: 15812119Trial
Studies on the bioequivalence of second generation cephalosporins: cefaclor capsules and suspension.
Koytchev Rossen, Ozalp Yildiz, Erenmemisoglu Aydin et al. · Arzneimittelforschung · 2004
PMID: 15497664Trial
[Comparative study on cefdinir and cefaclor in the treatment of patients with mild to moderate bacterial community acquired pneumonia].
Jiang Xing-tang, Du Yan-ping, Deng Li-ping · Zhonghua Yi Xue Za Zhi · 2004
PMID: 15631797Trial
Etiology of acute otitis media in childhood and evaluation of two different protocols of antibiotic therapy: 10 days cefaclor vs. 3 days azitromycin.
Oğuz Fatma, Unüvar Emin, Süoğlu Yusufhan et al. · Int J Pediatr Otorhinolaryngol · 2003
PMID: 12560149Trial
Low plasma cefaclor levels in cystectomized bladder cancer patients with various types of urinary diversion.
Mattioli F, Tognoni P, Corbu C et al. · Eur J Clin Pharmacol · 2003
PMID: 12610750Trial
A comparative study of cefaclor vs amoxicillin/clavulanate in pediatric pharyngotonsillitis.
Haczyński Józef, Chmielik Mieczysław, Bien Stanisław et al. · Med Sci Monit · 2003
PMID: 12640354Trial
Antibiotic prophylaxis by low-dose cefaclor in children with vesicoureteral reflux.
Kaneko Kazunari, Ohtomo Yoshiyuki, Shimizu Toshiaki et al. · Pediatr Nephrol · 2003
PMID: 12736811Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefaclor (substance)
SNOMED CT
387270009
UMLS CUI
C0007537
RxNorm CUI
2176
Labeler
Rebel Distributors Corp

Clinical Data

This intervention maps to 14 entities in the Ltrl knowledge graph.

14
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.